Six of Seven: How an FDA Advisory Committee Voted Against Its Own Scientists on Peptide Compounding
The Vote on BPC-157 Was 8 Yes, 6 No, 1 Abstention
As reported by Doctor Mike, the FDA Pharmacy Compounding Advisory Committee reviewed seven peptides in a single sitting, among them BPC-157, which has been examined for ulcerative colitis. The committee voted on whether this substance should join the 503A bulks list, a list that governs what compounding pharmacies may use to prepare medicines that are not otherwise commercially available in that exact form.
The committee voted 8 in favour, 6 against, with 1 abstention on BPC-157 specifically. That is a narrow split, not a consensus, and it came after FDA staff scientists had already recommended against adding it.
The same pattern repeated across the other six peptides under review, including KPV and TB-500, both examined for wound healing and inflammatory conditions, and MOTS-c, examined for obesity and osteoporosis. By the end of the meeting, 6 of the 7 peptides had been recommended by the committee despite the scientific staff's advice against every one.
Four Questions the Committee Is Supposed to Answer
The committee's review process is not a vote on whether a substance is fashionable or widely discussed. It is structured around four specific questions for each substance under consideration.
First, can the substance be reliably identified and manufactured to a consistent standard. Second, what safety concerns does it raise. Third, is there evidence that it works for the condition being discussed. Fourth, is there a documented history of use in compounding practice.
FDA staff scientists apply these four questions and, for all seven peptides reviewed at this meeting, concluded the answers did not support inclusion. The committee, made up of outside experts and industry representation as well as FDA staff, reached a different conclusion on six of the seven substances.
A Recommendation Is Not a Rulemaking
A committee vote is advice, not law. Adding any substance to the 503A bulks list requires the FDA to complete a formal rulemaking process, which is separate from and slower than a committee meeting.
This distinction matters because a compounding pharmacy's ability to use a substance depends on the substance's actual legal status on the list, not on how an advisory committee voted about it. Until rulemaking is finished, none of the six recommended peptides has been added to the list as a matter of law.
It also matters because a place on the bulks list, if and when it happens, is not the same thing as FDA approval of that peptide as a medicine for the public. Approval is a distinct regulatory pathway with its own evidence requirements, and nothing in this committee's vote constitutes approval of BPC-157, KPV, TB-500 or MOTS-c for any condition.
What This Means Where You Live
Most peptides discussed at this kind of hearing are prescription-only medicines in Australia, meaning their supply and use sits under separate regulatory arrangements to the compounding bulks list debate happening in the United States.
An FDA committee recommendation, even a 6 of 7 result, does not change the regulatory status of these substances in Australia. The TGA states its own scheduling and approval decisions independently, based on its own evidence review, not on the outcome of a US advisory committee meeting.
The practical takeaway is that a committee's advisory vote, however close or lopsided, is one procedural step among several. Rulemaking, scheduling decisions and formal approval pathways remain the points where actual legal status changes, and those steps had not concluded at the time of this reported meeting.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.